teaser
↓Article continues below this sponsored advert↓
↑Advertisement↑
Adding capecitabine to gemcitabine in patients with advanced pancreatic cancer and a good Karnofsky performance score (KPS) prolongs survival, research has found.
The phase III trial, published in the Journal of Clinical Oncology, investigated the efficacy and safety of gemcitabine alone or in combination with capecitabine. It involved 319 advanced/metastatic pancreatic cancer patients randomised to receive either (a) oral capecitabine 650mg/m2 twice daily on days 1
